United States was the largest of Bio-Rad Laboratories, Inc.’s 4 reported lines in fiscal 2025, at $2.05B — 40% of $5.17B.
| Geography | FY 2009 | FY 2010 | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $2.31B | $2.24B | $2.08B | $2.05B | |||||||||||||
| Europe | $1.70B | $1.64B | $1.67B | $1.76B | |||||||||||||
| Segement Geographical Group Europe | — | — | — | — | |||||||||||||
| Asia | $1.28B | $1.13B | $1.04B | $1.03B | |||||||||||||
| Pacific Rim | — | — | — | — | |||||||||||||
| Segment Geographcial Group Pacific Rim | — | — | — | — | |||||||||||||
| Other (Primarily Canada & Latin America) | $310.80M | $333.00M | $338.60M | $330.80M | |||||||||||||
| Segment, Geographical, Groups Of Countries, Group Four | — | — | — | — | |||||||||||||
| Total | $5.60B | $5.34B | $5.13B | $5.17B |
In fiscal 2025, which ended December 31, 2025, the 4 regions Bio-Rad Laboratories, Inc. reported in this breakdown added up to $5.17B. That was up 0.7% from $5.13B in fiscal 2024. United States was the largest region, at $2.05B or 39.6% of the total, followed by Europe ($1.76B, 34.1%) and Asia ($1.03B, 19.9%). Together, the two largest regions made up 73.7% of this total.
Compared with fiscal 2024, Europe grew the fastest, rising 5.7% to $1.76B. Other (Primarily Canada & Latin America) fell the most, down 2.3% to $330.80M. Over fiscal 2022 to 2025, revenue across these regions went from $5.60B to $5.17B, a compound annual decline of 2.7%. United States' share of the total fell from 41.2% to 39.6% over the same years.
The table also keeps 4 regions that Bio-Rad Laboratories, Inc. no longer reports, so earlier years can still be read on their original basis; use "Show 4 discontinued" beneath the table to see them. This breakdown covers every fiscal year from 2009 to 2025, as reported in Bio-Rad Laboratories, Inc.'s annual filings.
Clinical Diagnostics was the largest of Bio-Rad Laboratories, Inc.’s 2 reported lines in fiscal 2025, at $3.12B — 60% of $5.17B.
| Segment | FY 2009 | FY 2010 | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Clinical Diagnostics | $2.90B | $2.98B | $3.08B | $3.12B | |||||||||||||
| Life Science | $2.69B | $2.36B | $2.06B | $2.04B | |||||||||||||
| All Other Segments | $8.00M | $7.00M | $1.00M | — | |||||||||||||
| Total | $5.60B | $5.34B | $5.13B | $5.17B |
In fiscal 2025, which ended December 31, 2025, the 2 segments Bio-Rad Laboratories, Inc. reported in this breakdown added up to $5.17B. The segments reported changed from fiscal 2024, so the total is not directly comparable with the $5.13B reported that year. Clinical Diagnostics was the largest segment, at $3.12B or 60.5% of the total, followed by Life Science ($2.04B, 39.5%).
Compared with fiscal 2024, Clinical Diagnostics grew the fastest, rising 1.6% to $3.12B. Life Science fell the most, down 0.7% to $2.04B. Because segments were added or dropped between the two years, part of this reflects how Bio-Rad Laboratories, Inc. regrouped its reporting.
The table also keeps 1 segment that Bio-Rad Laboratories, Inc. no longer reports, so earlier years can still be read on their original basis; use "Show 1 discontinued" beneath the table to see them. This breakdown covers every fiscal year from 2009 to 2025, as reported in Bio-Rad Laboratories, Inc.'s annual filings.
Scenario, Previously Reported was the largest of Bio-Rad Laboratories, Inc.’s 2 reported lines in fiscal 2017, at $1.07B — 100% of $1.07B.
| Nature of Error | FY 2012 | FY 2012 | FY 2012 | FY 2013 | FY 2013 | FY 2013 | FY 2016 | FY 2016 | FY 2016 | FY 2017 | FY 2017 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scenario, Previously Reported | $942.40M | $1.03B | $1.02B | $1.00B | $1.01B | $1.07B | ||||||
| Scenario, Actual | — | — | — | — | — | — | ||||||
| Scenario, Adjustment | — | — | — | — | — | -$1.80M | ||||||
| Total | $942.40M | $1.03B | $1.02B | $1.00B | $1.01B | $1.07B |
In fiscal 2017, which ended September 30, 2017, the 2 revenue lines Bio-Rad Laboratories, Inc. reported in this breakdown added up to $1.07B. The revenue lines reported changed from fiscal 2017, so the total is not directly comparable with the $1.01B reported that year. Scenario, Previously Reported was the largest revenue line, at $1.07B or 100.2% of the total.
Scenario, Adjustment was first reported as a separate revenue line in fiscal 2017. Figures are shown as reported, so the total is net of Scenario, Adjustment, which was -$1.80M in fiscal 2017. The table also keeps 1 revenue line that Bio-Rad Laboratories, Inc. no longer reports, so earlier years can still be read on their original basis; use "Show 1 discontinued" beneath the table to see them. This breakdown covers 12 fiscal years between 2012 and 2017, as reported in Bio-Rad Laboratories, Inc.'s annual filings.
Bio-Rad Laboratories, Inc. (BIO) breaks its revenue down by region, segment and revenue line. In fiscal 2025, its largest region was United States, with $2.05B or 39.6% of the total, followed by Europe at $1.76B (34.1%).
United States was Bio-Rad Laboratories, Inc.'s largest region in fiscal 2025, with $2.05B in revenue, 39.6% of the $5.17B reported across its 4 regions.
Clinical Diagnostics was Bio-Rad Laboratories, Inc.'s largest segment in fiscal 2025, with $3.12B in revenue, 60.5% of the $5.17B reported across its 2 segments.
Scenario, Previously Reported was Bio-Rad Laboratories, Inc.'s largest revenue line in fiscal 2017, with $1.07B in revenue, 100.2% of the $1.07B reported across its 2 revenue lines.
Of the Bio-Rad Laboratories, Inc. regions reported in both fiscal 2024 and fiscal 2025, and making up at least 2% of the total, Europe grew the fastest, rising 5.7% from $1.67B to $1.76B.
Every figure is taken from Bio-Rad Laboratories, Inc.'s annual financial filings and shown as reported: each line keeps the name the company gives it, years follow its own fiscal calendar, and lines it has stopped reporting stay in the table for the years they were reported.
The breakdown by region covers fiscal 2009 to 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.